67 related articles for article (PubMed ID: 30365122)
21. Overcoming EGFR
Fassunke J; Müller F; Keul M; Michels S; Dammert MA; Schmitt A; Plenker D; Lategahn J; Heydt C; Brägelmann J; Tumbrink HL; Alber Y; Klein S; Heimsoeth A; Dahmen I; Fischer RN; Scheffler M; Ihle MA; Priesner V; Scheel AH; Wagener S; Kron A; Frank K; Garbert K; Persigehl T; Püsken M; Haneder S; Schaaf B; Rodermann E; Engel-Riedel W; Felip E; Smit EF; Merkelbach-Bruse S; Reinhardt HC; Kast SM; Wolf J; Rauh D; Büttner R; Sos ML
Nat Commun; 2018 Nov; 9(1):4655. PubMed ID: 30405134
[TBL] [Abstract][Full Text] [Related]
22. Population Based Testing for Primary Prevention: A Systematic Review.
Manchanda R; Gaba F
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30400647
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis.
Wang W; Song Z; Zhang Y
Arch Med Sci; 2018 Oct; 14(6):1298-1307. PubMed ID: 30393484
[TBL] [Abstract][Full Text] [Related]
24. Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.
Tagliamento M; Genova C; Rijavec E; Rossi G; Biello F; Dal Bello MG; Alama A; Coco S; Boccardo S; Grossi F
Expert Opin Pharmacother; 2018 Dec; 19(18):2055-2062. PubMed ID: 30392436
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic microRNA-411 promotes lung carcinogenesis by directly targeting suppressor genes SPRY4 and TXNIP.
Zhang C; Wang H; Liu X; Hu Y; Ding L; Zhang X; Sun Q; Li Y
Oncogene; 2019 Mar; 38(11):1892-1904. PubMed ID: 30390072
[TBL] [Abstract][Full Text] [Related]
26. EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
Jiang T; Chu Q; Wang H; Zhou F; Gao G; Chen X; Li X; Zhao C; Xu Q; Li W; Wu F; Xiong A; Zhao J; Xu Y; Su C; Ren S; Zhou C; Hirsch FR
Int J Cancer; 2019 May; 144(10):2605-2612. PubMed ID: 30387880
[TBL] [Abstract][Full Text] [Related]
27. Differential Burden of Rare and Common Variants on Tumor Characteristics, Survival, and Mode of Detection in Breast Cancer.
Li J; Ugalde-Morales E; Wen WX; Decker B; Eriksson M; Torstensson A; Christensen HN; Dunning AM; Allen J; Luccarini C; Pooley KA; Simard J; Dorling L; Easton DF; Teo SH; Hall P; Czene K
Cancer Res; 2018 Nov; 78(21):6329-6338. PubMed ID: 30385609
[TBL] [Abstract][Full Text] [Related]
28. Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib.
Bøttcher TM; Cold S; Jensen AB
Acta Oncol; 2019 Feb; 58(2):147-153. PubMed ID: 30375908
[TBL] [Abstract][Full Text] [Related]
29. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
[TBL] [Abstract][Full Text] [Related]
30. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
[TBL] [Abstract][Full Text] [Related]
31. Implications of Transglutaminase-Mediated Protein Serotonylation in the Epigenetic Landscape, Small Cell Lung Cancer, and Beyond.
Lin J; Wu SC
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831672
[TBL] [Abstract][Full Text] [Related]
32. The role of protein acetylation in carcinogenesis and targeted drug discovery.
Yang J; Song C; Zhan X
Front Endocrinol (Lausanne); 2022; 13():972312. PubMed ID: 36171897
[TBL] [Abstract][Full Text] [Related]
33. Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug-gene interaction networks analysis.
MotieGhader H; Tabrizi-Nezhadi P; Deldar Abad Paskeh M; Baradaran B; Mokhtarzadeh A; Hashemi M; Lanjanian H; Jazayeri SM; Maleki M; Khodadadi E; Nematzadeh S; Kiani F; Maghsoudloo M; Masoudi-Nejad A
Sci Rep; 2022 Jun; 12(1):9417. PubMed ID: 35676421
[TBL] [Abstract][Full Text] [Related]
34. [Research Progress of Epigenetic Mechanism in Acquired Resistance of
Targeted Therapy in Non-small Cell Lung Cancer].
Ai X; Wang Y
Zhongguo Fei Ai Za Zhi; 2021 Oct; 24(10):705-713. PubMed ID: 34696542
[TBL] [Abstract][Full Text] [Related]
35. EGFR phosphorylates HDAC1 to regulate its expression and anti-apoptotic function.
Bahl S; Ling H; Acharige NPN; Santos-Barriopedro I; Pflum MKH; Seto E
Cell Death Dis; 2021 May; 12(5):469. PubMed ID: 33976119
[TBL] [Abstract][Full Text] [Related]
36. Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.
Jenke R; Reßing N; Hansen FK; Aigner A; Büch T
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562653
[TBL] [Abstract][Full Text] [Related]
37. Nanomedicine of tyrosine kinase inhibitors.
Smidova V; Michalek P; Goliasova Z; Eckschlager T; Hodek P; Adam V; Heger Z
Theranostics; 2021; 11(4):1546-1567. PubMed ID: 33408767
[TBL] [Abstract][Full Text] [Related]
38. Cleavage of HSP90β induced by histone deacetylase inhibitor and proteasome inhibitor modulates cell growth and apoptosis.
Park S; Jeon JH; Park JA; Choi JK; Lee Y
Cell Stress Chaperones; 2021 Jan; 26(1):129-139. PubMed ID: 32869129
[TBL] [Abstract][Full Text] [Related]
39. Abnormal spindle-like microcephaly-associated protein (ASPM) contributes to the progression of Lung Squamous Cell Carcinoma (LSCC) by regulating CDK4.
Yuan YJ; Sun Y; Gao R; Yin ZZ; Yuan ZY; Xu LM
J Cancer; 2020; 11(18):5413-5423. PubMed ID: 32742488
[TBL] [Abstract][Full Text] [Related]
40. Increase of secondary mutations may be a drug-resistance mechanism for lung adenocarcinoma after radiation therapy combined with tyrosine kinase inhibitor.
Zhuang H; Shi S; Guo Y; Wang Z
J Cancer; 2019; 10(22):5371-5376. PubMed ID: 31632481
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
